-
Mashup Score: 2Day of Giving 2024 - 2 month(s) ago
When you give to what you love, you have a direct impact on our more than 3,360 students. Make your mark and give to what you love today!
Source: give.communityfunded.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Knowing Nothing Has Meant Everything | ASH Clinical News | American Society of Hematology - 5 month(s) ago
Aaron Gerds, MD, is the deputy director for clinical research at Cleveland Clinic Taussig Cancer Institute and associate professor at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. It’s hard to believe another zodiac has gone around and we are at the American Society of Hematology (ASH) annual meeting once again. Amid all the hustle and bustle, it is a great time to reflect. And as an MPN (myeloproliferative neoplasms) doc is prone to do, I’ve been thinking about Janus,
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
"Of course, this would be in violation of some rules of time travel – right, Biff?" Knowing Nothing Has Meant Everything https://t.co/CUPDg1eV7T https://t.co/UjSeKeKjdi
-
-
Mashup Score: 1Advances in Precision Oncology for Blood Cancers Webinar 3: Precision Medicine in Myeloproliferative Neoplasms | Front Line Genomics - 11 month(s) ago
Advances in Precision Oncology for Blood CancersTuesdays 6th, 13th and 20th June at 3 pm BST/4 pm CET/10 am ESTCancer has emerged as the most prominent area in which genomics has made significant s…
Source: Front Line GenomicsCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/VY63rlSnuW
-
-
Mashup Score: 0Clinical trial club | NCT03194542 trial: Luspatercept for the treatment of patients with anemic myelofibrosis - 11 month(s) ago
MPN Hub Symposium: NCT03194542 trial: Luspatercept for the treatment of patients with anemic myelofibrosis
Source: mpnhub-cme.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Thrilled to be joining @jjkiladjian for a journal club on June 28 to luspatercept and myelofibrosis! #mpnsm @MPN_Hub #CleClinicCancer https://t.co/1D0Uf3vcEL https://t.co/e5vRaNC8an
-
-
Mashup Score: 4Program Guide – ASCO Meeting Program Guide - 11 month(s) ago
AuthorsAaron Thomas GerdsCleveland Clinic, Cleveland, OHAaron Thomas Gerds, Claire Harrison, Jean-Jacques Kiladjian, Ruben A. Mesa, Alessandro M. Vannucchi, Rami S. Komrokji, Prithviraj Bose, Marina Kremyanskaya, Adam J. Mead, Jason R. Gotlib, Fabian Sanabria, Niloufar Marsousi, Ana Carolina Giuseppi, Huijing Jiang, Jeanne M. Palmer, Kelly McCaul, Vincent Ribrag, Srdan Verstovsek, Francesco…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Luspatercept can improve anemia and reduce transfusion dependency. Great step forward for patients! #Luspatercept #MFResearch #Hematology #mpnsm https://t.co/LfeAOUcMBj
-
-
Mashup Score: 1CANCER BUZZ: Myelofibrosis: Advances in Treatment and Therapy - 1 year(s) ago
The goal of treatment for most patients with myelofibrosis is to relieve symptoms. A provider will use a formula to assign a risk category (indicating aggressiveness) for the disease. Myelofibrosis categorized as low risk may not require treatment. Instead, a provider would monitor a patient’s health through regular checkup to watch for signs of disease progression. For those patients with…
Source: sites.libsyn.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Discussing new therapies in #mpnsm with @ACCCBuzz https://t.co/cY83CMWRZK
-
-
Mashup Score: 0Insights into the MOMENTUM Trial - 1 year(s) ago
Aaron Gerds talks about the MOMENTUM trial.
Source: Cleveland ClinicCategories: Hem/Oncs, Latest HeadlinesTweet-
Happy to talk to @ShepardDale on @CleClinicMD, Cancer Advances podcast to discuss myelofibrosis, JAK inhibitors, and the 48 week results from the MOMENTUM trial. https://t.co/scKWfExkwY #CleClinicCancer https://t.co/ytuL6YqReB
-
-
Mashup Score: 3Cleveland MPN Patient and Caregiver Program - 1 year(s) ago
Join MPN Advocacy & Education International for an upcoming MPN patient and caregiver program in Cleveland, OH. Dr. Aaron Gerds has invited our organization to Cleveland to host this exciting program to learn from top MPN Specialists and to get your questions answered. Topics and speakers will continue to be announced as we know more.
Source: Constant ContactCategories: Hem/Oncs, Latest HeadlinesTweet-
#CleClinicCancer #MPNsm Patient and Caregiver meeting coming up soon! with @mpnadvocacy. @hamiltkyb of @ClevelandClinic, Dr. Rossetti of @UPMCHillmanCC, and @JustinGrinnell4 of @StateofFitness https://t.co/typM7Rh3GB https://t.co/f4NmQ7kKP0
-
-
Mashup Score: 1
The FDA noted that additional requirements are needed prior to the approval of ruxolitinib extended-release for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease, in a complete response letter.
Source: Targeted OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
FDA Issues Complete Response Letter to Ruxolitinib XR Tablets for MPNs https://t.co/w3AD7m5zOT via @targetedonc
-
-
Mashup Score: 0
Skip Nav Destination January 20, 2023 Aaron Gerds, MD, is the deputy director for clinical research at Cleveland Clinic Taussig Cancer Institute and associate professor at Cleveland Clinic Lerner College of Medicine of Case…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Peddling Panaceas in @ASHClinicalNews https://t.co/wHBLP8dkue https://t.co/lrZOzCJ17j
-
Please join me in supporting this important cause! https://t.co/LqS5Gv3q43